A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Condition: Human Papillomavirus Infection Interventions: Biological: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli); Biological: Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine Sponsors: Beijing Health Guard Biotechnology, Inc; Jiangsu Province Centers for Disease Control and Prevention; National Institutes for Food and Drug Control, China; Nanjing Sangruisi Pharmaceutical Technology Co., Ltd; School of Public Health of Southeastern University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2023 Category: Research Source Type: clinical trials
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety Profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
Condition: Human Papillomavirus Infection Interventions: Biological: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli); Biological: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)(GARDASIL®) Sponsor: Beijing Health Guard Biotechnology, Inc Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 30, 2022 Category: Research Source Type: clinical trials